Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics Inc (TENX) is a clinical-stage pharmaceutical company developing therapies for cardiovascular and pulmonary diseases with high unmet needs. This page provides official updates on clinical trials, regulatory milestones, and corporate developments.
Investors and researchers will find a centralized repository of press releases and verified news related to Tenax's lead candidate levosimendan, including progress on the Phase 3 LEVEL study for PH-HFpEF. Track updates on intellectual property expansions, partnership announcements, and scientific presentations.
All content is curated to meet investor needs for timely, accurate information on drug development progress. Bookmark this page for direct access to primary source materials from Tenax Therapeutics, without promotional commentary or speculative analysis.
Tenax Therapeutics, Inc. (Nasdaq: TENX) has announced a 1-for-20 reverse stock split effective January 4, 2023, at 5:00 PM ET. This move aims to ensure compliance with Nasdaq's minimum bid price requirement. The total shares outstanding will decrease from 45,836,215 to approximately 2,291,811. Each stockholder's percentage ownership remains unchanged, except for minor adjustments to fractional shares. The adjusted shares will start trading on January 5, 2023. The reverse split was approved in June 2022 and will not affect the number of authorized shares or their par value.
On October 10, 2022, Tenax Therapeutics (Nasdaq: TENX) presented positive data from a study on PH-HFpEF patients treated with oral levosimendan during the Heart Failure Society of America Scientific Sessions. The open-label extension of the HELP trial showed oral levosimendan was safe and effective, with improvements in heart rate, blood pressure, and walking distance. No serious adverse events were reported. The company's Chief Medical Officer emphasized its potential for daily use compared to weekly IV treatments. This data supports advancing oral levosimendan into Phase 3 testing, addressing a significant unmet need.
Tenax Therapeutics (Nasdaq: TENX) announced a strategic review process aimed at maximizing shareholder value, supported by Roth Capital Partners. The company is developing TNX-201 and TNX-103 for pulmonary diseases, both of which are Phase 3-ready. Tenax believes its current valuation does not reflect its clinical assets' potential. The strategic evaluation may include options like a sale or merger, although no results are guaranteed. Additionally, the launch of the TNX-201 Phase 3 trial for pulmonary arterial hypertension has been postponed to 2023.
Tenax Therapeutics, Inc. (NASDAQ: TENX) announced a KOL webinar on TNX-201, an oral modified release imatinib for pulmonary arterial hypertension (PAH), scheduled for June 2, 2022, at 11:00 AM ET. Esteemed experts, including Dr. Anna Hemnes and Dr. John Ryan, will discuss TNX-201's potential role in PAH treatment and share insights from the Phase 3 IMPRES trial of imatinib. The company aims to advance TNX-201's development, affirming its commitment to addressing unmet needs in cardiovascular therapies.
Tenax Therapeutics (NASDAQ: TENX) announced the successful completion of its pharmacokinetic study for TNX-201, a modified release formulation of imatinib for treating pulmonary arterial hypertension (PAH). The new formulation significantly enhances relative bioavailability while minimizing gastric release, addressing gastrointestinal side effects. Manufacturing is underway to support the upcoming Phase 3 trial, IMPROVE, with patient enrollment expected to start in the second half of 2022.
Tenax Therapeutics, Inc. (NASDAQ: TENX) announced an agreement to issue 10,596,027 Units at $0.755 each, raising approximately $8 million. Each Unit includes a pre-funded warrant and a warrant to purchase shares of common stock. The gross proceeds will support clinical trials for levosimendan and imatinib, R&D, and general corporate purposes. Additionally, existing warrants for 9,206,120 shares will have their exercise price reduced to $0.63 and their term extended by two years, along with other warrants for 7,783,616 shares.
Tenax Therapeutics, Inc. (TENX) reported financial results for the year ended December 31, 2021, with a net loss of $32.5 million, equating to a loss of $1.58 per share, up from a loss of $9.9 million in 2020. R&D expenses surged to $25.1 million from $4.6 million, reflecting intensified efforts on their oral formulation of imatinib, TNX-201, aimed at treating pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 3 study of TNX-201 in the second half of 2022. Cash reserves stood at $5.6 million, expected to last until Q2 2022.
Tenax Therapeutics (NASDAQ: TENX) will present its late-stage drug candidates, imatinib and levosimendan, at the American College of Cardiology (ACC) Scientific Sessions from April 2-4, 2022, in Washington, D.C. The presentations include insights from the HELP trial on levosimendan for pulmonary hypertension related to left heart failure and discussions on next-generation tyrosine kinase inhibitors for PAH. These sessions feature renowned experts, including Professors Barry Borlaug and Stuart Rich, highlighting important advancements in cardiopulmonary therapies.
Tenax Therapeutics (TENX) announced the appointment of Robyn Hunter to its Board of Directors, effective January 28, 2022. Hunter, an independent director with extensive experience in development-stage biotechnology, will chair the audit and compliance committee. President and CEO Christopher T. Giordano expressed optimism about her contributions as the company advances its lead candidates, TNX-201 and TNX-102, into pivotal testing. Tenax focuses on treatments for cardiovascular and pulmonary diseases with high unmet needs.
Tenax Therapeutics (TENX) announced that the USPTO granted a patent for TNX-102, its subcutaneous formulation of levosimendan, aimed at treating pulmonary hypertension related to left heart failure (PH-HFpEF). The patent, issued on January 4, 2022, extends until at least 2039, allowing for treatment claims for various health conditions beyond PH-HFpEF. This development underscores the company's commitment to address unmet medical needs in cardiovascular diseases. Tenax plans to advance TNX-102 into pivotal Phase 3 testing based on encouraging clinical trial results.
